https://www.selleckchem.com/products/raptinal.html
The goal of this study was to estimate the relative efficacy of acalabrutinib (monotherapy and in combination with obinutuzumab) compared with standard frontline treatments for chronic lymphocytic leukemia (CLL) in fludarabine-ineligible patients, through a network meta-analysis (NMA). The efficacy of acalabrutinib from ELEVATE-TN (study of Obinutuzumab+Chlorambucil, Acalabrutinib [ACP-196]+Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL) was compared to bendamustine + rituximab, chlorambucil-based therapy, al
Like
Comment
Share
